According to Future Market Insights, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market demand is predicted to develop at a 9.5% CAGR from 2023 to 2033. The global market for Castration-Resistant Prostate Cancer (CRPC) Treatment is estimated to reach a value of US$ 28 billion by 2033. The increasing frequency of CRPC, together with increased knowledge and diagnosis of the disease, is one of the primary drivers of market expansion. Furthermore, the industry is being driven by the emergence of innovative medications with higher efficacy and fewer adverse effects than established therapy.
Get Sample Report + Related Graphs & Charts@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16739
The rising usage of combination therapy is another major factor driving the growth of the CRPC treatment market. Physicians can better target cancer and enhance treatment outcomes by combining different medications and treatments. Combining targeted medicines with immunotherapies, for example, has showed potential in preliminary research.
The use of tailored medicines is one of the most promising advancements in CRPC treatment. These medications are meant to specifically target cancer cells and inhibit their development and spread while causing the least amount of harm to healthy cells. Targeted medicines such as enzalutamide and abiraterone have demonstrated considerable improvements in the treatment of CRPC, leading to their approval by regulatory agencies worldwide.
Key Takeaways from the Market Study
- Castration-Resistant Prostate Cancer (CRPC) Treatment Market is predicted to increase at a 9.5% CAGR from 2023 to 2033.
- In terms of medication delivery mode, the oral route is estimated to account for 55% of the castration-resistant prostate cancer (CRPC) therapy market in 2023.
- In 2023, North America is estimated to have 46% of the market for castration-resistant prostate cancer (CRPC) treatment.
- In 2023, Europe is predicted to hold 40% of the market for castration-resistant prostate cancer (CRPC) treatment.
“The development of new targeted therapies, immunotherapies, and combination therapies is driving this growth, and there is significant potential for continued innovation in the years to come.” states an FMI analyst
To remain ‘ahead’ of your competitors, Ask a Question@ https://www.futuremarketinsights.com/ask-question/rep-gb-16739
Competitive Landscape
Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation
- Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
- in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.
Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey
Therapy Type:
- Hormonal therapy
- Chemotherapy
- Immunotherapy
- Radiotherapy
Drug Class:
- Antineoplastic
- Non-steroidal Antiandrogen
- Corticosteroids
- Microtubule Inhibitor
Drug Delivery Method:
- Oral Route
- Injectable Route
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16739
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs